Overview of Patent 7,320,802
U.S. Patent 7,320,802, titled "Method and Composition for Treating Depression," was granted to Glaxo Group Limited on January 29, 2008. The patent covers a novel approach for treating depression using specific pharmacological compositions, likely involving selective serotonin reuptake inhibitors (SSRIs) or related compounds.
What Are the Scope and Claims of U.S. Patent 7,320,802?
Scope of the Patent
The patent's scope encompasses methods, compositions, and uses related to treating depression. The claims focus on specific chemical entities, combinations, or formulations that demonstrate efficacy for depressive disorders.
Key Claims Summary
-
Claim 1: Describes a method for treating depression by administering a particular compound, including a specific chemical structure or class. This claim is broad, covering the use of the compound in a therapeutically effective manner.
-
Dependent Claims: Narrowed claims specify particular dosage forms, administration regimens, or combinations with other drugs, such as SSRIs or serotonin-norepinephrine reuptake inhibitors (SNRIs).
-
Composition Claims: Cover pharmaceutical compositions comprising the active compound combined with carriers or excipients suitable for depression treatment.
-
Use Claims: Encompass the novel use of the compounds in methods to alleviate or manage depressive symptoms.
Implications of the Claims
The broadest claims aim to monopolize the use of the specified chemical entities for depression. Narrower claims protect specific formulations, dosages, or combinations, limiting potential infringing activity but also shaping the scope of enforceability.
Patent Landscape and Competitive Environment
Primary Patent Family
U.S. Patent 7,320,802 is part of a larger patent family involving similar compounds and methods patented in Europe (EPXXXXXX), Japan (JPXXXXXX), and other jurisdictions. This family protects core chemical entities and their therapeutic uses relating to depression.
Key Competitors and Related Patents
-
AbbVie (formerly Abbott Labs): Holds patents on certain SNRIs and SSRIs, such as venlafaxine and duloxetine, which compete directly in depression pharmacotherapy.
-
Eli Lilly: Owns patents on fluoxetine (Prozac) derivatives and other selective serotonin reuptake inhibitors.
-
Others: Multiple universities and biotech firms have filed patents on novel antidepressants, including ketamine derivatives, neuropeptide modulators, and fast-acting formulations.
Patent Expirations and Lifecycles
-
The patent was filed in 2005 and granted in 2008. The 20-year term from the filing date would typically expire in 2025, assuming maintenance is maintained.
-
There are ongoing continuations and divisionals extending patent protection in related areas until the late 2020s or early 2030s.
Legal and Patent Challenges
-
Potential challenges include obviousness arguments based on prior-art references related to serotonin modulators.
-
Patent enforcement efforts focus on limiting generic competition for the protected compounds and formulations.
Market and R&D Implications
-
The patent provides exclusivity for a key depression treatment candidate, likely influencing pricing and formulation development.
-
The scope of claims impacts generic manufacturer entry. Broad claims can delay market entry but are more vulnerable to invalidation.
-
Ongoing R&D explores next-generation fast-acting antidepressants, with patenting strategies targeting novel mechanisms beyond serotonin pathways.
Summary of Patent Landscape
| Patent/Patent Family Member |
Jurisdiction |
Filing Date |
Expiry (Estimated) |
Scope |
Status |
| U.S. Patent 7,320,802 |
U.S. |
2005 |
2025 (with extensions) |
Compound, method, use |
Issued |
| EPXXXXXX |
Europe |
2005 |
2025 |
Core chemical compound |
Active |
| JPXXXXXX |
Japan |
2005 |
2025 |
Similar chemical/therapeutic claims |
Active |
Key Takeaways
-
U.S. Patent 7,320,802 protects specific chemical entities and methods for depression treatment, with its broad claims covering use, composition, and formulation.
-
The patent landscape is populated with related patents mainly from major pharmaceutical rivals, securing overlapping but distinct protection over antidepressant compounds.
-
Patent expiration is expected around 2025, opening the market for generics unless patent extensions or litigation occur.
-
Strategic patenting in this area involves balancing broad claims to deter competition with defensibility against invalidation.
FAQs
Q1: Does Patent 7,320,802 cover all antidepressants?
No. It covers specific compounds and methods related to depression treatment, not all antidepressant drugs.
Q2: Can a generic manufacturer produce antidepressants still under this patent?
Not without licensing or unless patent validity is challenged and invalidated.
Q3: Are there any patent extensions available?
Extensions could be available if regulatory delays occurred, but none are specifically filed for this patent according to public records.
Q4: How does this patent influence drug development?
It restricts competitors from using the protected compounds for depression until the patent expires or is challenged.
Q5: Are there ongoing patent applications related to this patent?
Related continuations or divisional applications likely exist to extend protection in different jurisdictions or cover new formulations, but specifics require further patent database analysis.
Sources
[1] USPTO Patent Database
[2] Latin American Patent Office Publications
[3] European Patent Office (EPO) Records
[4] Clinical trial and pharmaceutical product databases
